Roivant Social Ventures is proud to announce the launch of our inaugural Convergence Forum Fellowship Program in support of CEOs championing healthcare equity through the development of therapeutics and technology.
"Most of the treatments and cures that pharmaceutical companies focus on are for illnesses that affect white men, rather than women or people of color, said Lindsay Androski, CFA, President and CEO of Roivant Social Ventures and an independent director at Eloxx Pharmaceuticals.
“I do not believe this is because of malice but because people have a human tendency to want to make a difference in areas that have impacted them or their loved ones personally,” Androski told BioSpace. “But one area where I can make an impact today is to expose more talented future leaders to the industry and get them in the front door at the beginning of their careers.”
Roivant Sciences and Roivant Social Ventures Launch Inaugural Diversity in Pharma Internships for Talented PharmD Students
Taught by Lindsay Androski, RSV Founder and CEO, and Scott Singleton, Associate Professor at the UNC Eshelman School of Pharmacy
Reflecting on a Remarkable Year of Progress: A Letter from Roivant Social Ventures President & CEO Lindsay Androski
Roivant Social Ventures Publishes Global Access Scorecard to Guide Impact Investors in Making Equitable Investment Decisions
The Gregor G. Peterson Prize in Venture Philanthropy is awarded annually to a trailblazing start-up in the non-profit sector.
Vanderbilt University Medical Center (VUMC) and Roivant Social Ventures (RSV) announced an intention to collaborate in developing therapies…
Roivant Social Venture's new program is set to launch its first cohort of students in fall 2023. (Advarra)
Roivant Social Ventures announced a major collaboration with Sanford Burnham Prebys, San Diego’s prestigious medical discovery institute…
The Research Acceleration and Innovation Network (TRAIN) is an affinity network of foundations interested in taking a more strategic and entrepreneurial approach—what some refer to as “venture philanthropy”—to their role as funders of medical research.
Advances in scientific research suggest the possibility of a viable biosynthetic blood technology that could radically transform the health outcomes of people around the world. Such a development would enhance a drastically insufficient global supply of red blood cells needed for transfusions, while also mitigating severe risks to donor supply precipitated by future pandemic or environmental catastrophes. However, insufficient funding is obstructing necessary further development. There is a pressing need for focused investment to advance scientific development, and an opportunity for government and philanthropic funds to help ensure that safe, efficacious biosynthetic blood becomes commercializable in a manner that enables global affordable access.
“If you’re a woman or person of color, your health is being hurt by a lack of diversity in healthcare.”
RSV CEO Lindsay Androski celebrates a woman-led company that received FDA approval for a serious unmet need in women’s health, argues that more diverse leaders will increase industry focus on the needs of diverse patients, and talks about RSV’s efforts to address this issue through a first-of-its-kind program to train tomorrow’s diverse leaders in real-world drug development focused on unmet needs!
Stay tuned for another exciting announcement on that soon, as well as more details about RSV’s work to use existing technology to improve the lives of patients living with sickle cell disease.
The COVID-19 pandemic has underscored the importance of equitable distribution of vaccines and therapeutics for LMICs, and small-footprint manufacturing platforms that can be flexibly adapted to produce a wide variety of products and scaled to meet regional demand offer a compelling alternative to conventional pharmaceutical-manufacturing facilities.
Health Affairs Forefront published an article co-written by Andrew Spencer Goldman, RSV’s General Counsel & Head of Policy, about ways in which the NIH, the world’s most important funder of biomedical research, should approach global equitable access moving forward.
Nearly every philanthropist asks the same question when reviewing the impact of their giving: How can I do the most good for the most people?
Corporate America is exceedingly generous. With nearly $17 billion in donations in 2020 alone, businesses are working hard to address everything from equity to education to addiction.
The gene and cell therapy field saw its first approved treatments in Europe in 2012 and the United States in 2017 and is projected to be at least a $10B USD industry by 2025.
“Policy Outlook: Understanding the Environment for Pricing and Access to Medicines During an Election Year.”
Lindsay Androski, Roivant Social Ventures CEO, speaks at SOCAP Global on the panel, “Fast, Friendly, and Effective - Disruptive Philanthropy Fueling Equal Opportunity and Entrepreneurship.”
Listen to Lindsay Androski, Roivant Social Ventures Founder & CEO, speak with John Shegerian on the Impact Podcast.
Video recording featuring Lindsay Androski, RSV CEO, and Andrei Iancu, Former Under Sec. of Commerce for IP and Director of the US Patent & Trademark Office
Video recording featuring Lindsay Androski, RSV CEO, and Andrei Iancu, Former Under Sec. of Commerce for IP and Director of the US Patent & Trademark Office
Video recording featuring Lindsay Androski, RSV CEO, and Andrei Iancu, Former Under Sec. of Commerce for IP and Director of the US Patent & Trademark Office
